Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Glioblastoma 2Brain Neoplasms 2Sarcoma, Endometrial Stromal 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms 1Melanoma 1Kidney Neoplasms 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Temozolomide 14Bevacizumab 11Erlotinib Hydrochloride 5Radiotherapy 4Carboplatin 4Magnetic Resonance Spectroscopy 3Irinotecan 3Immunoglobulin G 3Disulfides 3temsirolimus 2poly ICLC 2palbociclib 2etoposide phosphate 2antineoplaston AS 2-1 2antineoplaston A10 2Vincristine 2Sunitinib 2Sirolimus 2Everolimus 2Dasatinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1varlilumab 1vandetanib 1trebananib 1trametinib 1terameprocol 1tandutinib 1selinexor 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Oligodendroglioma × trebananib × Clear all
NCT01609790 2022-07-21

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

National Cancer Institute (NCI)

Phase 2 Completed
137 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡